NEWSROOM
Onchilles Pharma to Present OP-NEU-101 Trial in Progress at ESMO Congress 2026
N17350 is designed to leverage the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while sparing healthy tissue, including immune cells. In preclinical studies, N17350 demonstrated broad tumor-killing activity, immune cell preservation, and activation of anti-tumor immunity across multiple solid tumor models.
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors
N17350 is designed to leverage the ELANE pathway, a cancer-selective mechanism that induces immunogenic cancer cell death while sparing healthy tissue, including immune cells. In preclinical studies, N17350 demonstrated broad tumor-killing activity, immune cell preservation, and activation of anti-tumor immunity across multiple solid tumor models.
PIONEERING THE USE OF THE ELANE PATHWAY TO CREATE THE NEXT-GENERATION OF PAN-CANCER THERAPEUTICS
Subscribe To Our Newsletter
Keep up to date with all the latest news from Onchilles Pharma